decision (not covered in class?) Based on the pyramid of social responsibility‚ Merck is required to be profitable (base). Since the research of development will never be profitable to shareholders Merck should do develop the drug. Based on Merck’s actual value system‚ it wants to be ethical and even be a good corporate citizen. So Merck should conduct the research. Question 8 - If you were the senior executive of Merck‚ what would you do? (Open question) I would make assessment of the potential costs
Premium Social responsibility Corporation Business ethics
Merck Ethics Study In developing a drug to combat river blindness‚ pharmaceutical company Merck discovered an opportunity to treat millions of affected peoples around the world that probably would never see commercial use. The drug in development‚ ivermectin‚ was unaffordable to the primary victims of river blindness‚ Third World peoples. Thus‚ Dr. Vagelos‚ the head of research at the time‚ treaded upon a ethical quagmire; he could either choose to scrap the drug and its further research or
Premium Ethics Philosophy of life Person
heart attacks f) Merck blamed naproxen for skewing the results against Vioxx 3) New England Journal of Medicine Omission g) Merck omits three heart attacks from article submission h) Inclusion of omitted data caused a significantly greater result 4) FDA Reaction i) Letter regarding downplay of risks j) Addition of warning label to Vioxx k) Additional study results 5) Approve Study l) Results with placebo group cause Merck to recall drug
Premium Coronary artery disease Aspirin Hypertension
1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999‚ and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research‚ and (2) developing partnerships with smaller biotechnology companies. Since 1995‚ Merck had launched
Premium Expected value License Money
Analysis on Merck: Conflict and change Assessment: Merck is one of the biggest pharmaceutical companies in the world today. Although encountered with success‚ it still faces many problems today while trying to be the market leader competing against its competition. While being research and development driven company‚ Merck now has to go beyond R&D to stay competitive in the pharmaceutical industry. The main issue that seems to come
Premium Pharmaceutical industry Pharmacology
including Bayer AG and Novartis are exploring a deal for Merck & Co Inc’s consumer healthcare business‚ as they seek to gain scale in a fragmented industry‚ according to several people familiar with the matter. Reckitt Benckiser Group PLC and Procter & Gamble Co are also among the parties that have held discussions with Merck about buying the unit‚ best known for Coppertone sunscreen and Claritin allergy medicine‚ the sources said this week. The Merck business‚ which also includes Dr. Scholl’s foot
Premium Pharmacology Marketing Pharmacy
TO: Dr. Roy Vagelos‚ Chairman and CEO Merck Corporation. January‚ 1991. The decision to move forward with the program to donate the new drug Mectizan on a large scale to the affected population in the Third World needs to be systematically analyzed. There are two especially important angles from which this decision needs to be considered. The first concern that needs to be taken into account is that of the stockholders and investors in this company‚ whose interests you are ultimately charged with
Premium Medicine Pharmacology Pharmacy
margins‚ which made them invest little in new technology and productivity improvement of the product process. If they were to encounter technical issues or problems‚ they generally added more labor or scheduled overtime. Vertical Integration Sourcing: With vertical integration sourcing the process is fully owned and operated by the VF Corp. This mode of sourcing had a proven track record of producing high quality products‚ very efficient and reliable. However‚ this sourcing is capital intensive
Premium
The University of Chicago The Booth School of Business of the University of Chicago The University of Chicago Law School Vertical Integration‚ Appropriable Rents‚ and the Competitive Contracting Process Author(s): Benjamin Klein‚ Robert G. Crawford‚ Armen A. Alchian Source: Journal of Law and Economics‚ Vol. 21‚ No. 2 (Oct.‚ 1978)‚ pp. 297-326 Published by: The University of Chicago Press for The Booth School of Business of the University of Chicago and The University of Chicago Law School
Premium Contract Economics Monopoly
c. Moody’s Investors Service downgraded the long-term senior unsecured rating of AZN from A1 to Aa2 in 2007. Assess any potential association between this downgrade and AZN’s arrangements with Merck. Paris‚ July 30‚ 2007 -- Moody’s Investors Service downgraded the long-term senior unsecured ratings of AstraZeneca plc and its guaranteed subsidiary to A1 from Aa2. This downgrade followed the announcement of AstraZeneca’s acquisition of MedImmune for a total consideration of more than US$15 billion
Premium Money